AsymBio raises $184M to scale biologics manufacturing
What's the deal? Shanghai-based AsymBioDealroom has a profile for this one. Try Dealroom → has raised RMB 1.2397 billion (about $184 million) in a growth equity round led by parent company Asymchem GroupDealroom has a profile for this one. Try Dealroom → and Hillhouse Qirui. Asymchem contributed roughly $156 million, Hillhouse Qirui about $26 million. The deal lifts Asymchem's stake in the biologics contract developer to 83.5%.
What's the endgame? AsymBio is a contract development and manufacturing organisation (CDMO) focused exclusively on biologics. Backed by Asymchem's 30 years of experience, it offers end-to-end services from early development to commercial-scale manufacturing.
What's the money for? The capital will fund capacity expansion and the scaled delivery of client programs. AsymBio has been investing in R&D platforms, GMP manufacturing lines, and high-containment facilities, aiming for a clearer path to profitability.
By the numbers: AsymBio generated roughly RMB 470 million ($70 million) in revenue in 2025. First-quarter 2026 revenue exceeded RMB 140 million ($21 million), signalling steady growth as the round closes.
Why now? Pipelines for antibody-drug conjugates (ADCs), novel drug conjugates, and bispecific and multispecific antibodies are moving rapidly into clinical development. Outsourcing demand from biotech and large pharmaceutical firms in China and globally continues to expand.
The signal: Hillhouse Qirui's participation reflects investor conviction in the biologics CDMO sector, where complex modalities like ADCs are driving fresh outsourcing demand. For AsymBio, the injection buys scale at a moment when manufacturers positioned in high-growth drug classes stand to capture that spending.
Read more: PR Newswire
Image credit: jurvetson
